Dexmethylphenidate hydrochloride is under clinical development by Cingulate and currently in Phase III for Attention Deficit Hyperactivity Disorder (ADHD). According to GlobalData, Phase III drugs for Attention Deficit Hyperactivity Disorder (ADHD) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Dexmethylphenidate hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dexmethylphenidate hydrochloride overview
Dexmethylphenidate hydrochloride is under development for the treatment of attention deficit hyperactivity disorder (ADHD). The drug candidate is administered orally and formulated as tablet. It is developed based on Cingulate’s innovative Precision Timed Release (PTR) drug delivery platform technology
Cingulate operates as a holding company. It develops drugs for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety associated disorders through its subsidiary. The company is headquartered in Kansas City, Kansas, the US.
For a complete picture of Dexmethylphenidate hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.